Prudential Financial Inc. purchased a new position in shares of Enzo Biochem, Inc. (NYSE:ENZ) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 17,830 shares of the medical research company’s stock, valued at approximately $149,000.

A number of other large investors have also bought and sold shares of ENZ. Trexquant Investment LP purchased a new position in Enzo Biochem during the first quarter valued at $115,000. Campbell & CO Investment Adviser LLC boosted its position in Enzo Biochem by 24.4% in the first quarter. Campbell & CO Investment Adviser LLC now owns 14,325 shares of the medical research company’s stock valued at $120,000 after buying an additional 2,812 shares during the last quarter. JPMorgan Chase & Co. purchased a new position in Enzo Biochem during the first quarter valued at $220,000. Nine Chapters Capital Management LLC boosted its position in Enzo Biochem by 63.1% in the first quarter. Nine Chapters Capital Management LLC now owns 50,400 shares of the medical research company’s stock valued at $422,000 after buying an additional 19,500 shares during the last quarter. Finally, Teachers Advisors LLC boosted its position in Enzo Biochem by 60.7% in the fourth quarter. Teachers Advisors LLC now owns 112,023 shares of the medical research company’s stock valued at $777,000 after buying an additional 42,302 shares during the last quarter. Institutional investors and hedge funds own 61.39% of the company’s stock.

Shares of Enzo Biochem, Inc. (NYSE ENZ) opened at 11.17 on Wednesday. The firm has a market capitalization of $518.37 million, a price-to-earnings ratio of 15.67 and a beta of 0.98. The stock’s 50 day moving average price is $10.88 and its 200 day moving average price is $8.56. Enzo Biochem, Inc. has a 12-month low of $4.88 and a 12-month high of $12.04.

COPYRIGHT VIOLATION NOTICE: “17,830 Shares in Enzo Biochem, Inc. (ENZ) Acquired by Prudential Financial Inc.” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.thecerbatgem.com/2017/07/26/prudential-financial-inc-takes-position-in-enzo-biochem-inc-enz-updated.html.

ENZ has been the topic of several analyst reports. Zacks Investment Research lowered Enzo Biochem from a “buy” rating to a “hold” rating in a report on Tuesday, May 16th. BidaskClub raised Enzo Biochem from a “buy” rating to a “strong-buy” rating in a report on Wednesday, July 19th.

Enzo Biochem Company Profile

Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.

Institutional Ownership by Quarter for Enzo Biochem (NYSE:ENZ)

Receive News & Stock Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related stocks with our FREE daily email newsletter.